Organization | Neuropsychiatric Research Institute, Fargo, ND

Neuropsychiatric Research Institute, Fargo, ND Report issue

Academic/Hospital Phase 3 Phase 4

Founded: Fargo ND United States (1955)

Status: Acquired by Sanford Research (2018)

Organization Overview

First Clinical Trial

2006

NCT00636896

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Neuropsychiatric Research Institute, Fargo, North Dakota

Active Ingredients

Drugs in Phase 4 Trials (6)

bupropion (wellbutrin) (1 trial)

buspirone (buspar) (1 trial)

grapefruit juice (1 trial)

lisdexamfetamine (vyvanse) (1 trial)

topiramate (topamax) (1 trial)

venlafaxine (effexor) (1 trial)

Drugs in Phase 3 Trials (3)

duloxetine (Cymbalta) (1 trial)

pramipexole (mirapex) (1 trial)

sertraline (zoloft) (1 trial)

Drugs in Other Trials (3)

ethanol (1 trial)

modafinil (provigil) (1 trial)

olanzapine (zyprexa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Binge-Eating Disorder (Phase 3)

Bulimia (Phase 4)

Bulimia Nervosa (Phase 4)

Disease (Phase 3)

Feeding and Eating Disorders (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 10
# of Trial APIs: 12